RxTally.CA — Canadian maple leaf logoClarity in every comparison.
Health Canada recalls

September Apo-Semaglutide recall: check the 4 mg pen and lot number

If you use Apo-Semaglutide, another recall headline may sound familiar. This one needs a fresh look at the package: Health Canada’s September notice identifies a different pen and lot from its August notice. The practical question is whether the product you have matches the new record.

By RxTallyLast Update 4 min read

Key takeaways

  • The affected product is Apo-Semaglutide 4 mg/pen, concentration 1.34 mg/mL, DIN 02568012, lot 7000636A.
  • The pen may show and deliver 0.25 mg or 0.5 mg instead of the expected 1 mg.
  • Health Canada records a Type II recall at the retailer level. Check your product and consult a healthcare professional before discontinuing it.
  • The recall date is September 23. The notice lists September 25 as its original publication date and September 24 as its last update.

Start with the package, not the headline

Apo-Semaglutide is the product name, but the name alone is not enough to identify an affected pen. For this notice, match the eight-digit DIN 02568012 and lot 7000636A alongside the 4 mg/pen presentation and 1.34 mg/mL concentration.

Have the package available when you contact your pharmacist. If the identifiers are difficult to find or read, ask the pharmacy to help rather than trying to identify the pen from an online photograph. The pharmacist can compare what was dispensed with the official notice.

Source: Health Canada: affected product and lot, RA-82679

What is wrong with the affected lot?

Health Canada says the affected lot may display 0.25 mg or 0.5 mg in the dose window and deliver one of those amounts instead of the expected 1 mg. The notice concerns both what the window shows and what the pen delivers.

The 4 mg figure describes the pen presentation; it is not the dose described in the failure report. Keep those two numbers separate when discussing the notice with a pharmacist. This article does not provide instructions to adjust a pen or compensate for a possible dose problem.

Why this is separate from the August recall

The August article on RxTally concerns the 2 mg/pen presentation, DIN 02568020, lot 7000599A. The September record is for the 4 mg/pen presentation, DIN 02568012, lot 7000636A. The August notice describes a possible 2 mg display and delivery instead of 0.25 mg or 0.5 mg; September describes the lower amounts instead of an expected 1 mg. The reported failure modes are different too.

The similar recall titles make the two notices easy to confuse. Our view is straightforward: a previous check against the August notice does not answer whether a package matches September’s affected lot. Keep the notices separate and check the identifiers again. Neither notice should be read as a blanket recall of every semaglutide product.

Source: Health Canada: separate August Apo-Semaglutide notice

What to do if you may have the affected product

Health Canada asks people to verify whether their product is affected and consult their healthcare provider before discontinuing it, or about any health concerns. Recall questions can also be directed to the recalling company, Apotex.

A useful opening for the pharmacy conversation is: “Can you check whether my Apo-Semaglutide pen matches recall RA-82679, DIN 02568012, lot 7000636A?” Ask the pharmacist what action applies to your specific package. Do not rely on an article to decide whether to stop treatment or change how you use the pen.

The notice labels the recall Type II and its depth as retailers. That does not remove the need for a person who already has a pen to check the product and seek the advice set out in the notice.

Three dates, kept exactly as the source lists them

The official record gives September 23, 2026 as the recall date, September 25 as the original publication date, and September 24 as the last-updated date. The update therefore precedes the stated publication date. We have retained the discrepancy rather than inventing a corrected sequence.

The Last Update date at the top of this article records our review of the source. It does not turn the September event into a new October recall. For any later changes to affected lots or instructions, consult the current Health Canada notice.

Frequently asked questions

Is every Apo-Semaglutide pen recalled?

This September notice identifies one presentation and lot: 4 mg/pen, DIN 02568012, lot 7000636A. Ask a pharmacist to check your package against the current official notices.

Is this the same recall reported in August?

No. The August notice and this September notice identify different DINs and lots. A matching manufacturer or headline is not enough to treat them as the same event.

Should I stop using my medication?

Health Canada advises consulting your healthcare provider before discontinuing the affected product or about health concerns. Contact your pharmacist to establish whether your package is affected and what to do next.

Sources & further reading

Related reading